AstraZeneca returns to China's CSPC for $18.5B obesity deal
AstraZeneca returns to China's CSPC for $18.5B obesity deal
Body unavailable. Use the original source.
AstraZeneca returns to China's CSPC for $18.5B obesity deal
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.